冠状动脉和衰老:皮肤冠状动脉干预的生理基础,评估和治疗选择
Mohamed Abdirashid1, Umberto Barbero2, Chiara Cavallino1
1Sant'Andrea Hospital, 13100 Vercelli, Italy.
Journal of cardiovascular development and disease
|July 26, 2024
概括
冠状动脉化是动脉样硬化的一个关键部分,需要了解,以获得更好的穿皮冠状动脉干预 (PCI) 结果. 本综述侧重于冠心内成像和一种新的算法,用于管理结石冠心病变.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 动脉样硬化研究 动脉样硬化研究
背景情况:
- 冠状动脉化是一种复杂的病理过程,有助于动脉样硬化的进展.
- 广泛的化变得越来越普遍,并且与皮肤穿冠状动脉干预 (PCI) 的不良结果有关.
- 目前的药理疗法在改变已建立的化方面是无效的,这凸显了需要改进的诊断和管理策略的需要.
研究的目的:
- 审查冠状动脉内成像技术在冠状动脉化诊断和管理中的作用.
- 提出一种实用的算法,用于选择严重化冠状动脉病变的初始治疗策略.
- 通过临床案例示例来说明拟议的算法的应用.
主要方法:
- 关于冠状动脉化病原和管理的当前文献的全面审查.
- 评估可用的冠心内成像方式 (如IVUS,OCT).
- 为干预心脏病学家开发和介绍决策算法.
主要成果:
- 冠内成像为化病变提供了至关重要的解剖学和组织学见解.
- 拟议的算法提供了一个结构化的方法来选择首选的第一线治疗策略.
- 案例研究表明,该算法在复杂的化冠状动脉干预中成功应用.
结论:
- 冠状动脉化的有效管理需要对其病原和先进的成像技术有充分的了解.
- 拟议的算法有助于优化严重冠状动脉化患者的治疗选择.
- 进一步的研究和成像指导策略的临床验证对于改善PCI结果在这个患者群体中至关重要.
更多相关视频
08:02Author Spotlight: Enhanced Quantification of Cardiovascular Calcification Progression for Longitudinal Micro PET/CT Studies in Small Research Animals
Published on: November 15, 2024
581
04:40Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans
Published on: August 28, 2018
15.1K
相关概念视频
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
481
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
481
